TABLE 1.
Baseline and clinical characteristic of patients with or without IAa
| Population | Variableb | Overall (n = 500) |
IA patients (n = 103) |
Non-IA patients (n = 397) |
P value |
|---|---|---|---|---|---|
| Discovery | Demographics | ||||
| Age (avg no. of yrs ± SD) | 51.96 ± 15.20 | 51.94 ± 12.80 | 51.97 ± 15.78 | 0.986 | |
| Sex ratio (no. of males/no. of females) | 1.16 (269/231) | 2.03 (69/34) | 1.02 (200/197) | 0.003 | |
| No. (%) with hematological disease: | |||||
| AML | 354 (70.80) | 66 (64.08) | 288 (72.54) | 0.092 | |
| ALL | 65 (13.00) | 17 (16.50) | 48 (12.09) | 0.235 | |
| Other | 81 (16.20) | 20 (19.42) | 61 (15.37) | 0.320 | |
| Allo-SCT | 202 (40.40) | 46 (44.66) | 156 (39.29) | 0.323 | |
| No. (%) who ever received prophylaxis | 268 (66.83) | 36 (49.31) | 232 (70.94) | 0.0008 | |
| (n = 474) | (n = 94) | (n = 380) | |||
| Replication | Demographics | ||||
| Age (avg no. of yrs ± SD) | 52.48 ± 16.57 | 51.38 ± 17.32 | 52.75 ± 16.43 | 0.512 | |
| Sex ratio (no. of males/no. of females) | 1.53 (287/187) | 2.24 (65/29) | 1.41 (222/158) | 0.056 | |
| No. (%) with hematological disease: | |||||
| AML | 252 (53.28) | 50 (53.19) | 203 (53.42) | 0.912 | |
| ALL | 75 (15.86) | 21 (22.58) | 54 (14.21) | 0.076 | |
| Other | 146 (30.87) | 23 (24.73) | 123 (32.37) | 0.174 | |
| Allo-SCT | 157 (33.19) | 31 (33.33) | 127 (33.42) | 0.968 | |
| No. (%) who ever received prophylaxis | 182 (63.85) | 38 (61.29) | 144 (64.57) | 0.744 | |
| (n = 974) | (n = 197) | (n = 777) | |||
| Overall | Demographics | ||||
| Age (avg no. of yrs ± SD) | 52.23 ± 15.89 | 51.74 ± 15.10 | 52.36 ± 16.10 | 0.612 | |
| Sex ratio (no. of males/no. of females) | 1.33 (556/418) | 2.12 (134/63) | 1.19 (422/355) | 0.001 | |
| No. (%) with hematological disease: | |||||
| AML | 606 (62.22) | 116 (58.88) | 491 (63.19) | 0.265 | |
| ALL | 140 (14.37) | 38 (19.29) | 102 (13.13) | 0.028 | |
| Other | 227 (23.31) | 43 (21.83) | 184 (23.68) | 0.583 | |
| Allo-SCT | 359 (36.86) | 77 (39.09) | 283 (36.42) | 0.489 | |
| No. (%) who ever received prophylaxis | 450 (65.59) | 74 (54.81) | 376 (68.36) | 0.003 |
a
Abbreviations: Allo-SCT, allogeneic stem cell transplantation; AML, acute myeloid leukemia; ALL, acute lymphoid leukemia. P values of ≤0.05 were considered significant and are shown in bold.
b
Prophylaxis status was available for 400 subjects from the discovery cohort (73 IA and 327 non-IA patients) and 285 subjects from the replication cohort (62 IA and 223 non-IA patients).